Citations 1
Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension
Simpson, Catherine E. , Ambade, A.S., Harlan, Robert, Roux, Aurelie , Aja, Susan, Graham, David R. , Grünig, Gabriele , Aldred, Micheala A. , Comhair, Suzy , Griffiths, Megan , Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Mathai, Stephen C. , Damico, Rachel L. , Group, and the PVDOMICS Study, Aldred, Micheala A , Erzurum, Serpil C , Hill, Nicholas S , Hassoun, Paul M , Mathai, Stephen C , Simpson, Catherine E , Shah, Ami A. , Hummers, Laura K , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Rosenzweig, Erika B. , Barnard, John , Tang, W.H. Wilson , Rischard, Franz , Frantz, Robert P. , Hassoun, Paul M. , Group, and the PVDOMICS Study
American Journal of Physiology-Lung Cellular and Molecular Physiology | October 3, 2023 | Volume: 325 | Issue: 5 | Pages: L617-L627
Our study shows an early increase in kynurenine pathway metabolism in at-risk subjects with systemic sclerosis who develop pulmonary arterial hypertension (PAH). We show that kynurenine pathway upregulation precedes clinical diagnosis and that this metabolic shift is associated with increased disease severity and shorter survival times. We also show that gene expression of TDO2, an enzyme that generates kynurenine from tryptophan, rises with PAH development.